Related MeSH Hierarchy (5)
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Skin Diseases, Genetic » Dermatitis, Atopic
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Dermatitis » Dermatitis, Atopic
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Diseases, Eczematous » Dermatitis, Atopic
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Skin Diseases, Genetic » Dermatitis, Atopic
Diseases [C] » Immune System Diseases [C20] » Hypersensitivity » Hypersensitivity, Immediate » Dermatitis, Atopic
Description
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. MeSH
Hierarchy View
Approved Indicated Drugs (14)
Phase 4 Indicated Drugs (32)
Phase 3 Indicated Drugs (37)
Phase 1 Indicated Drugs (43)
Organization Involved with Phase 4 Indications (67)
1st Allergy & Clinical Research Center
Atopic Dermatitis Research Network
Bernstein Clinical Research Center
Dell Children's Medical Center
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
National Institute for Health Research, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
Oregon Health and Science University
Society for Pediatric Dermatology
St. Luke's-Roosevelt Hospital Center
Technical University of Dresden
University of California, Davis
Organization Involved with Phase 3 Indications (58)
Gottfried Wilhelm Leibniz Universität Hannover
Hospital Padre Bento de Guarulhos
Kolderma Instituto De Pesquisa Clinica
Korea Research Institute of Bioscience & Biotechnology
Luigi Sacco University Hospital
Organization Involved with Phase 2 Indications (160)
Badalona Hospital Germans Trias i Pujol
BioMimetix Pharmaceutical, Inc.
Forest Hills Dermatology Group
Hemay Pharmaceutical PTY. LTD.
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hospital Universitario Virgen Macarena
Huazhong University of Science and Technology
Maccabi Healthcare Services, Israel
Mayanei Hayeshua Medical Center
National Cancer Institute (NCI)
National Polytechnic Institute, Mexico
Provectus Biopharmaceuticals, Inc.
Reistone Biopharma Company Limited
Sterna Biologicals GmbH & Co. KG
St. George Albert Clinic Zeged University Hospital
Suzhou Connect Biopharmaceuticals
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Technical University of Munich
Texas Dermatology and Laser Specialists
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universitaetsklinikum Schleswig-Holstein
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
Organization Involved with Phase 1 Indications (29)
Organization Involved with Other Experimental Indications (54)
Association pour la Recherche Clinique et Immunologique
Chinese Academy of Medical Sciences
Clinica Pediatrica Ospedale dei Bambini Vittore Buzzi
Cosmetique Active International
German Federal Ministry of Education and Research
Hospital General Dr. Manuel Gea Gonzalez
Institut National de la Santé Et de la Recherche Médicale, France
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Norwegian University of Science and Technology
Ospedale dei Bambini V. Buzzi Milano
Pontificia Universidad Catolica de Chile
Skin Investigation and Technology Hamburg GmbH
South African Medical Association
Spartanburg Regional Family Medicine
Swiss National Science Foundation
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
